Table 1 Characteristics of the clinical trials included in the meta-analysis
Study | Geographic locale | Study design | Sample size(female/male) | Age in years (mean ± SD) | HCV-RNA, copies/mL (mean ± SD) | HCV genotype 1/non-genotype 1 | HBV-DNA, copies/mL (mea ± SD) | ALT, U/L (mean ± SD) | IFN plus ribavirin regimen | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Â | Â | Â | Â | Â | Â | Drugs | Course, weeks | Follow-up, weeks |
Yu et al. [35] | China | Cohort | C: 10/40 | 44.9 ± 9.6 | 5.9 ± 1.4log10 | C: 30/20 | 4.6 ± 0.9log10 | 97 ± 19 | PegIFN-α2a, ribavirin | genotype 1: 48 non-genotype 1: 24 | 24 |
|  |  |  | M: 9/37 | 46.4 ± 11.3 | 6.3 ± 1.3log10 | M: 25/21 |  | 93 ± 18 |  |  |  |
Liu et al. [32] | Taiwan | Cohort | C: 56/105 | 51.1 ± 10.3 | 2.16 ± 3.4 × 106 | C: 97/64 | UD-4.22 × 105 | 121.0 ± 85.0 | PegIFN-α2a, ribavirin | genotype 1: 48 non-genotype 1: 24 | 24 |
|  |  |  | M: 71/89 | 48.9 ± 10.5 | 2.29 ± 4.1 × 105 | M: 110/50 |  | 126.1 ± 81.8 |  |  |  |
Chuang et al. [34] | Taiwan | Cohort | C: 11/31 | 45.04 ± 10.7 | 5.38 ± 0.96log10 | C: 21/21 | 2.64 ± 2.26log10 | 92.1 ± 73.0 | IFN-α2b | 24 | 24 |
|  |  |  | M: 22/62 | 44.9 ± 11.2 | 5.60 ± 0.94log10 | M: 48/36 |  | 141.1 ± 105.5 |  |  |  |
Hung et al. [30] | Taiwan | Cohort | C: 14/22 | 48.8 ± 12.6 | 5.80 ± 1.10og10 | C: 17/19 | NR | 125.8 ± 89.3 | IFN-α2b | 24 | 24 |
|  |  |  | M: 28/44 | 48.3 ± 12.0 | 5.80 ± 1.10og10 | M: 34/38 |  | 164.2 ± 139.9 |  |  |  |
Liu et al. [36] | Taiwan | Cohort | C: 5/19 | 46.5 ± 13.2 | 2.4 ± 3.1 × 106 | C: 14/7 | 1.3 ± 2.5 × 103 | 137.0 ± 81.0 | IFN-α2a | 24 | 24 |
|  |  |  | M: 12/18 | 48.5 ± 9.4 | 1.9 ± 2.2 × 106 | M: 17/13 |  | 177.0 ± 192.0 |  |  |  |